Lupin gets FDA nod for prostate cancer drug

Lupin gets FDA nod for prostate cancer drug — Lupin has received tentative approval from the USFDA for its prostate cancer treatment drug. The approval allows Lupin to launch the drug upon patent expiry or settlement. This move strengthens its oncology portfolio in the key US market. 📊 STOCKS: LUPIN | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #pharma